Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleomycin Electrosclerotherapy (BEST) for Low-flow Vascular Malformations
NCT07579962Phase 2Recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Sep 2026
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bleomycin in vascular malformation, sponsored by Institute of Oncology Ljubljana. Started Sep 2026; status: recruiting.
02
Drugs
bleomycin
03
Conditions
vascular malformation
Beyond the preview
Go deeper on NCT07579962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579962.